Gilead claims US government PrEP patents are invalid

Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control (CDC) HIV prevention patents are invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Gilead sues US govt for breach of contract over antiviral patents

29 April 2020 Gilead has escalated its dispute with the US federal government by filing a new lawsuit accusing it of improperly filing for patents covering HIV drug Truvada.

Americas

US government sues Gilead for patent infringement over HIV drugs

7 November 2019 The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.

Americas

Gilead challenges US govt patents on HIV drug Truvada

22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.

More features

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Gilead claims US government PrEP patents are invalid

More on this story

Editor's picks

Editor's picks

More features